These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28271398)

  • 1. Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
    Wang XJ; Chan A
    Curr Oncol Rep; 2017 Mar; 19(3):20. PubMed ID: 28271398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
    Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
    Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy.
    Chen C; Chan A; Yap K
    J Oncol Pharm Pract; 2013 Jun; 19(2):111-20. PubMed ID: 23014897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy.
    Zecha JAEM; Raber-Durlacher JE; Laheij AMGA; Westermann AM; Epstein JB; de Lange J; Smeele LE
    Support Care Cancer; 2019 Oct; 27(10):3667-3679. PubMed ID: 31222393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Initial management of febrile neutropenia].
    Badertscher L; Damak H; Mercier L; Décosterd D
    Rev Med Suisse; 2016 Aug; 12(526):1321-1325. PubMed ID: 28671776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
    Fust K; Parthan A; Maschio M; Gu Q; Li X; Lyman GH; Tzivelekis S; Villa G; Weinstein MC
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):39-52. PubMed ID: 28064553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
    Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
    Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
    Nguyen M; Jacobson T; Torres J; Wann A
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
    Nishiyama N; Takahashi S; Mizuno T; Uehara T; Hashimoto J; Kurimura Y; Masumori N
    Int J Clin Oncol; 2015 Oct; 20(5):1012-7. PubMed ID: 25652906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
    Lyman GH; Abella E; Pettengell R
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):190-9. PubMed ID: 24434034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018).
    Carmona-Bayonas A; Jimenez-Fonseca P; de Castro EM; Mata E; Biosca M; Custodio A; Espinosa J; Vázquez EG; Henao F; Ayala de la Peña F
    Clin Transl Oncol; 2019 Jan; 21(1):75-86. PubMed ID: 30470991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
    Inagaki M; Sato J; Nihei S; Kashiwaba M; Kudo K
    Gan To Kagaku Ryoho; 2016 May; 43(5):593-6. PubMed ID: 27210089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Causes of the emergency department visits in cancer patients: postchemotherapy toxicity].
    Buendía Bravo S; González Haba Peña E; García Sánchez R; Arrabal Durán P; Sánchez Fresneda MN; Sanjurjo Sáez M
    Farm Hosp; 2015 Nov; 39(6):333-7. PubMed ID: 26618377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-stratification management of febrile neutropenia in pediatric hematology-oncology patients: Results of a French nationwide survey.
    Delebarre M; Tiphaine A; Martinot A; Dubos F
    Pediatr Blood Cancer; 2016 Dec; 63(12):2167-2172. PubMed ID: 27569451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of febrile neutropenia in solid organ malignancies following chemotherapy.
    Lakshmaiah KC; Abhayakumar SM; Shetty R; Loknath D; Jayashree RS; Govindbabu K
    J Cancer Res Ther; 2014; 10(3):540-3. PubMed ID: 25313735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia.
    Khanfir A; Kridis WB; Masmoudi S; Mezghani S; Hammami A; Frikha M
    Rev Recent Clin Trials; 2016; 11(1):72-6. PubMed ID: 26486208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
    Carrato A; Guillén-Ponce C; Grande-Pulido E
    Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer.
    Aagaard T; Reekie J; Jørgensen M; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
    Cancer Med; 2020 May; 9(9):3033-3042. PubMed ID: 32144897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
    Netterberg I; Karlsson MO; Nielsen EI; Quartino AL; Lindman H; Friberg LE
    Br J Clin Pharmacol; 2018 Mar; 84(3):490-500. PubMed ID: 29178353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.